Amsacrine and Continuous-Infusion High-Dose Cytosine Arabinoside as Induction Therapy for Patients with Newly-Diagnosed Acute Myelogenous Leukemia

Abstract

The overall cure rate of adults with newly-diagnosed acute myelogenous leukemia (AML) treated with continuous infusion high-dose cytarabine (CIHDAC) is comparable to that with standard-dose ara-C plus anthracycline or amsacrine (AMSA). We tested whether the addition of AMSA to CIHDAC improves the outcome of adults with untreated AML. 75 patients with untreated AML were treated with AMSA (75 mg/m²/day x 4) plus CIHDAC (1.5 g/m²/day x 4) for induction and, if in complete remission (CR), early and late intensification. Results were compared to those in 129 patients treated on a previous study with CIHDAC alone. The principal comparison in both groups was between those 117 patients (AMSA/CIHDAC n = 52, CIHDAC n = 65) who met the initial eligibility criteria for the AMSA/CIHDAC study (risk of early mortality ≤. 1) and who were treated at a time when relatively few eligible patients were excluded (19% in the AMSA/CIHDAC group, 34% in the CIHDAC group). There was no difference between regimens in CR rate, remssion duration, or survival in this cohort. When attention was turned to all 204 patients, outcome was superior with AMSA/CIHDAC very largely as a result of outcome in patients with APL. Aside from these patients, addition of amsacrine to CIHDAC did not appear to be productive.

Key Words:

• amsacrine
• high-dose cytarabine
• acute myelogenous leukemia